A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Clinical trial NCT02213263 · COMPLETED
Trial details
- NCT number
- NCT02213263
- Sponsor
- Pfizer
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-30
- Primary completion
- 2017-10-23
- Enrollment
- 394
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.